Stockreport

Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]

Kymera Therapeutics, Inc.  (KYMR) 
PDF The development follows the release of positive phase 1 data on the candidate on Dec. 8 that sent shares surging KT-621 is currently in phase 2. More on Kymera Ther [Read more]